Drugs / ARV-393
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06393738 | Sep 2024 → Mar 2028 expected | B-cell non-Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma | Arvinas Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Arvinas Inc. | Results Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update arvinas.com ↗
Announced there have been multiple responses in early cohorts of both B-and T-cell lymphomas in the first-in-human Phase 1 trial in patients with non-Hodgkin lymphoma (NHL). |
| 2025-06-13 | Arvinas Inc. | Results Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress arvinas.com ↗
ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI also known as AITL) and PDX models of transformed follicular lymphoma (tFL). |
| 2025-04-28 | Arvinas Inc. | Results Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting arvinas.com ↗
Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (SOC) chemotherapy, SOC biologics, and investigational oral small molecule inhibitors (SMIs) in high grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL) models. |
| 2024-06-21 | Arvinas Inc. | Results Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 arvinas.com ↗
Data presented at EHA showed anti-tumor activity for the company’s investigational PROTAC BCL6 degrader, ARV-393, in preclinical models of B-cell lymphoma. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARV-393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06393738 ↗ |
| Action | Inhibit | “ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas” NCT06393738 ↗ |
| Route | Oral | “The investigational drug will be given as an oral tablet” NCT06393738 ↗ |